Wahl Discusses Game Changing FDA-Approved Prostate Cancer Therapy

Dr. Richard Wahl, Director of Mallinckrodt Institute of Radiology, posing for a portrait on a summer day in Hope Plaza on the Washington University School of Medicine Campus.

Richard L. Wahl, MD, director of Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis, sat down with Fox 5 DC to discuss how recent advancements in nuclear medicine could be a game-changer for identifying and treating disease like prostate cancer. Wahl, a nuclear medicine expert and current president of the Society of Nuclear Medicine and Molecular Imaging, says the new FDA-approved PET imaging agent PyL is able to detect tiny cancer foci, which could help better physicians’ ability to find the cancer and recommend appropriate therapy treatments.